MedTrace Logo

Tranexamic Acid During Upper GI Endoscopic Resection Procedures

NCT05688020 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2023-08-09

No results posted yet for this study

Summary

Endoscopic resection of gastrointestinal lesions may prevent cancer. However, resection is associated with adverse events such as bleeding. Tranexamic acid (TXA) is a synthetic derivative of lysine that exerts antifibrinolytic effects and may prevent bleeding. The investigators aim to evaluate the effect of local TXA on preventing intraprocedural and postprocedural bleeding in patients undergoing endoscopic mucosal resection (EMR) of upper gastrointestinal lesions.

Conditions

  • Gastric Polyp
  • Gastric Neoplasm
  • Duodenal Neoplasms
  • Esophageal Neoplasms

Interventions

DRUG

Tranexamic acid

Tranexamic acid will be injected as part of the injectate during endoscopic resection.

DRUG

Epinephrine injection

Epinephrine will be injected as part of the standard injectate used during endoscopic resection.

Sponsors & Collaborators

  • Assaf-Harofeh Medical Center

    lead OTHER_GOV

Principal Investigators

  • Anton Bermont, MD · Assaf-Harofeh Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2025-02-28
Completion
2026-02-28

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05688020 on ClinicalTrials.gov